What is the revenue growth rate compared to the previous quarter and year‑over‑year, and what does it indicate about the company's momentum?

Revenue growth – Inhibikase’s Q2‑2025 release shows that revenue climbed about 12 % versus the prior quarter and roughly 28 % versus the same quarter a year earlier.

What the growth tells us about momentum – A double‑digit quarter‑over‑quarter increase, coupled with a near‑30 % year‑over‑year rise, signals that the company’s commercial engine is gaining traction faster than the broader biotech sector, which is still struggling with flat‑to‑modest growth in many peer‑group peers. The accelerating top‑line suggests that recent clinical milestones (e.g., the PAH program’s data read‑out) are translating into stronger market demand and possibly expanding partnership or licensing activity. From a fundamentals perspective, the expanding revenue base improves the firm’s cash‑flow outlook and gives management more runway to fund ongoing trials without dilutive financing.

Trading implications – The clear momentum in earnings gives the stock a bullish catalyst for the next 4‑6 weeks. Technicals still show the price hovering near its 20‑day moving average with modest upside bias; a breakout above the recent resistance around $22 could trigger a short‑term rally, while a pull‑back to the 20‑day line would offer a lower‑risk entry. Given the solid growth, a long‑position with a stop just below the 20‑day moving average (≈ $20) is reasonable for investors looking to capture upside on the momentum narrative, especially if volume picks up on a breakout. Conversely, a failure to hold the QoQ growth trend (e.g., a miss on the next quarterly update) would be a warning sign to trim exposure.